• Moleculin said its pivotal MIRACLE Phase 2B/3 trial is evaluating Annamycin plus cytarabine versus control in adults with relapsed or refractory acute myeloid leukemia after induction therapy.
• Blinded preliminary results have already been reported for the first 30 treated subjects, showing a 40% composite complete remission (CRc) rate.
• The trial protocol includes early unblinding at 45 subjects, with interim data unblinding expected in mid-2026.
• Moleculin also announced a targeted investigator-initiated Phase 1B/2 study of Annamycin in third-line pancreatic cancer that is expected to begin in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-008949), on March 19, 2026, and is solely responsible for the information contained therein.